Endocrine Abstracts

Objective: Cinacalcet, a calcimimetic that reduces parathyroid hormone (PTH) secretion and serum calcium (S-Ca) levels by increasing the sensitivity of calcium-sensing receptors has been introduced for the treatment of patients with persistent or recurrent primary hyperparathyroidism (PHPT). Within a prospective, non-interventional cohort study we identified patients with newly diagnosed PHPT who have been started on cinacalcet. Patient characteristics, treatment indications a...